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Abstract
Introduction Chemokines are a superfamily of small peptides 
involved in leukocyte chemotaxis and in the induction of 
cytokines in a w ide range of infectious diseases. Little is known 
about their role in meningococcal sepsis in children and their 
relationship with disease severity and outcome.
Methods Monocyte chemoattractant protein (MCP)-1, 
macrophage inflammatory protein (MIP) 1a, growth-related 
gene product (G RO )-a and interleukin (IL)-8 were measured in
5 8  children w ith meningococcal sepsis or septic shock on 
admission and 2 4  hours thereafter. Nine patients died. Serum 
chemokine levels of survivors and nonsurvivors were compared, 
and the chemokine levels were correlated with prognostic 
disease severity scores and various laboratory parameters.
Results Extremely high levels of all chemokines were measured 
in the children's acute-phase sera. These levels were
significantly higher in nonsurvivors compared w ith survivors and 
in patients with septic shock compared w ith patients with sepsis 
(P <  0.0001). The cutoff values of 65 ,407 pg/ml, 85,427 pg/ml 
and 460 pg/ml for monocyte chemoattractant protein, for IL-8 
and for macrophage inflammatory protein 1 a , respectively, all 
had 100%  sensitivity and 9 4 -9 8 %  specificity for nonsurvival. 
Chemokine levels correlated better with disease outcome and 
severity than tumor necrosis factor (TNF)-a and correlated 
similarly to interleukin (IL)-6. In available samples 24 hours after 
admission, a dramatic decrease of chemokine levels was seen.
Conclusion Initial-phase serum levels of chemokines in patients 
with meningococcal sepsis can predict mortality and can 
correlate strongly w ith disease severity. Chemokines may play a 
key role in the pathophysiology of meningococcal disease and 
are potentially new targets for therapeutic approaches.
Introduction
Neisseria m ening itid is  is one of the most feared causative 
agents in childhood infectious diseases, mainly affecting chil­
dren be low  the age of four and adolescents. It can cause men­
ingitis, sepsis and sep tic  shock, characterized by a rapid 
development of petechiae or purpura fulminans. M eningococ­
cal lipopolysaccharide, a constituent of the bacterial outer 
membrane, plays a central role in the pathophysiology of 
m eningococcal sepsis. The release of large amounts of 
lipopolysaccharide into the blood stream induces a cascade of 
reactions by the host immune response, including massive 
activation of the com plement system, activation of the coagu­
lation system and the induction of proinflammatory and anti­
inflammatory cytokines. H igh levels of these inflammatory 
mediators, such as tum or necrosis factor alpha (TNF-a) and IL- 
6, are associated w ith disease fatality.
Chemokines belong to a family of more than 40 relatively small 
peptides, which are involved in chem oattraction and activation 
of leukocytes to the site of inflammation and in the induction of 
cytokine production. Chemokines are thus key determ inants of 
inflammatory reactions and immunity [1-3]. These peptides are 
secreted by tissue cells, leucocytes and activated epithelial 
cells [4]. Four different subfamilies can be identified based on
CI =  confidence interval; ELISA =  enzyme-linked immunosorbent assay; GRO-a =  growth-related gene product alpha; IL =  interleukin; MCP-1 =  
monocyte chemoattractant protein 1; MIP-1 a  =  macrophage inflammatory protein 1a; PRISM =  Pediatric Risk of Mortality; RANTES =  regulated on 
activation, normal T cell expressed and secreted; TNF-a =  tumor necrosis factor alpha.
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the highly conserved presence of the first two cysteine resi­
dues, which are either separated or not by other amino acids: 
the C C  chemokines, the C X C  chemokines, the C X3C  chem ­
okines and the C  chemokines [5]. Chemokines act through a 
family of chemokine receptors, which are present on cell types 
such as leukocytes, dendritic cells and endothelial cells.
C X C  chemokines, which include growth-related gene product 
alpha (G RO -a) and IL-8, are potent chem oattractants fo r neu­
trophils, whereas the C C  chemokines, including monocyte 
chem oattractant protein 1 (MCP-1) and m acrophage inflam­
matory protein 1a (MIP-1a), attract monocytes, lymphocytes, 
basophils, eosinophils and natural killer cells. The C  and CX3C  
chemokine families are represented by only one chemokine 
each: lymphotactin and fractalkine, respectively. Lymphotactin 
is thought to be mainly involved in chem oattraction of lym- 
pocytes whereas fractalkine, a membrane-bound molecule 
expressed on endothelial cells, mediates the capturing and 
adhesion of circulating leucocytes [6,7].
Chemokines and their receptors play an important role in the 
innate immunity against infectious diseases such as HIV/AIDS 
and malaria, but also play an important role in autoimmune dis­
eases [8,9]. The role of chemokines in m eningococcal sepsis 
or septic shock has not so far been studied intensively. In 
m eningococcal disease, lipo-oligosaccharide and outer mem­
brane proteins of the m eningococcus induce a strong inflam­
matory response in patients. Studies in patients w ith bacterial 
meningitis, caused by N. m eningitid is, S trep tococcus pn eu ­
m oniae  or H aem ophilus influenzae, showed high levels of IL-
8 and MCP-1 in cerebrospinal fluid and variably increased lev­
els of G R O -a  and MIP-1 a  [10-13]. In studies of chemokines 
in patients w ith m eningococcal sepsis or sep tic  shock, only 
serum levels of IL-8 and RANTES (regulated on activation, nor­
mal T cell expressed and secreted) have been reported. IL-8 
levels are positively correlated w ith disease severity and out­
come, as opposed to RANTES, which is significantly lower in 
patients w ith severe disease and in nonsurvivors [14-16].
The aim of this study was to measure the serum levels of C X C  
and C C  chemokines during the initial phase of m eningococcal 
sepsis in children and to determ ine the ir relationship w ith d is­
ease severity and outcome.
Materials and methods
Patients
Children w ith a clinical diagnosis of m eningococcal sepsis or 
sep tic  shock were included between July 1997 and March 
2000  and between Decem ber 2001 and July 2002  after w rit­
ten informed consent was obtained from their parents or legal 
guardians. This retrospective study was approved by the m ed­
ical eth ics com m ittee of Erasmus MC.
Inclusion criteria for m eningococcal sepsis were: age between 
1 month and 18 years, a petechial rash and/or purpura fulmin-
ans, tachycardia, tachypnea and a body tem perature < 3 6 °C  or 
>38 .5 °C . Inclusion criteria fo r m eningococcal septic shock 
were all of the aforementioned and either persistent hypoten­
sion despite adequate volume supplem entation or two or more 
features of poor end-organ perfusion: pH < 7.3, base deficit < ­
5 or plasma lactate > 2 .0  mmol/l; arterial hypoxia defined as 
p O 2 < 7 5  mmHg, a p O 2/F iO 2 ratio < 2 5 0  or T cS aO 2 saturation 
< 9 6 %  in patients w ithout pre-existing pulmonary disease, 
acute renal failure defined as urine output < 0 .5  m l/kg/hour for 
at least 1 hour despite adequate fluid volume loading and w ith ­
out renal disease, or a sudden deterioration of baseline mental 
status not resulting from m eningitis [17].
As soon as possible, but at least within six hours after adm is­
sion to the pediatric intensive care unit, blood was drawn from 
an arterial line and serum and plasma samples were collected 
and stored at -80°C  until assays were performed. For this 
study, either serum or plasma was used to measure chem ok­
ines by means of ELISA. W hen the arterial line was still 
present, blood was again drawn 24 hours after inclusion and 
serum or plasma samples were collected and stored.
Thirty-eight children w ith a m eningococcal septic shock par­
tic ipated in a randomized, p lacebo-controlled dose-finding 
study of protein C  concentrate [18]. In this study children 
received either placebo or one of three dosages of protein C  
concentrate every 6 hours for the first 3 days, fo llowed by 
every 12 hours w ith a maximum of 7 days. Serum samples 
used in the present study were drawn just before infusion of 
the study m edication and 24 hours after the start of the treat­
ment.
Assays
Serum levels of G RO -a, MIP-1 a  and MCP-1 were measured 
by ELISA (Quantikine; R&D Systems (Minneapolis, MN, USA) 
according to the manufacturer's instructions. Samples were 
first diluted 1:2 in the appropriate buffer and, when chemokine 
concentrations of chemokines were above the upper limit of 
the standard curve of the assay, additional dilutions up to 
1:500 were made. The lower detection limit for G R O -a, MIP- 
1a and MCP-1 was 20 pg/m l. IL-8 levels were also measured 
by ELISA (Sanquin, Amsterdam, The Netherlands). C linical 
data were collected at inclusion, and the Pediatric Risk of M or­
tality (PRISM) score, the Sepsis-related Organ Failure A ssess­
ment score (adapted fo r pediatric use) and the Disseminated 
Intravascular Coagulation score were assessed fo r all patients 
on adm ittance to determ ine the disease severity [19-21]. Lab­
oratory parameters including white blood cell counts, lactate 
concentrations and serum C-reactive protein were measured 
on admission.
Statistical analysis
Clinical scores and parameters of patients are presented as 
means and 95%  confidence intervals (CIs). For statistical anal­
ysis, samples w ith chemokine levels be low  the detection limit
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F igure  1
Levels of growth-related gene product alpha (GRO-a), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1a (MIP- 
1a), IL-8, tumor necrosis factor alpha (TNF-a) and IL-6 in survivors versus nonsurvivors of meningococcal sepsis or septic shock. Black lines in 
boxes represent median values, boxes represent interquartile ranges, bars represent the 10th and 90th percentiles, and black dots are outlying val­
ues.
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Table  1
Spearm an co rre la tio n  co e ffic ie n ts  be tw een serum  chem ok ine  levels, la b o ra to ry  param eters fo r  d isease seve rity  and d isease 
severity  scores on adm iss ion
Sepsis-related 
Organ Failure 
Assessment 
score
Disseminated
Intravascular
Coagulation
score
Lactate White blood 
cells
C-reactive
protein
D-dimers Fibrinogen
IL-8 0.62 0.70 0.41 -0.57 -0.35 0.53 -0.69
MIP-1a 0.79 0.72 0.59 -0.66 -0.47 0.64 -0.83
GRO-a 0.78 0.72 0.52 -0.70 -0.43 0.66 -0.81
MCP-1 0.68 0.78 0.51 -0.70 -0.50 0.60 -0.79
GRO-a, growth-related gene product alpha; MCP-1, monocyte chemoattractant protein 1; MIP-1 a, macrophage inflammatory protein 1 a.
were assessed as the value of the detection limit of the assays. 
Chemokine levels are presented as the median, percentiles 
and ranges. Differences in chemokine levels between survi­
vors and nonsurvivors were analyzed by M ann-W hitney U 
tests. Differences in chemokine levels between different time 
points were analyzed by the W ilcoxon S igned Ranks test. 
Receiver-operating characteristic curves were calculated for 
all chemokines to determ ine the optimum cutoff values in pre­
dicting disease outcome. Correlations between chemokine 
levels and disease severity parameters were investigated by 
calculating Spearman's rho correlation coefficient (rs). All tests 
were two-tailed and P  <  0 .05 was considered significant.
Results
Patients
Fifty-eight patients were included, of which six had a m eningo­
coccal sepsis and 52 had septic shock according to the crite ­
ria. The median age of the patients was 4.0 years (range 0 .1 ­
16.1 years). Nine patients died of septic shock (15.5% ), all but 
one within 24 hours of admission. Thirty-seven patients 
needed ventilatory support at the time of first sampling (64% ). 
The mean PRISM score on admission was 22.0 (95%  CI,
1 9 .6 -24 .4 ), the mean Sepsis-related Organ Failure Assess­
ment score was 10.2 (95%  CI, 9 .0 -1 1 .3 ) and the mean Dis­
seminated Intravascular Coagulation score was 5.1 (95%  CI,
4 .6 -5 .7 ). The mean lactate concentration was 4.4 mmol/l 
(95%  CI, 3 .8 -5 .0 ), the mean C-reactive protein level was 96 
m g/l (95%  CI, 7 7 -1 1 4 ) and the mean white blood cell count 
was 11.6 X 109/l (95%  CI, 9 .4 -1 3 .8 ). The mean interval 
between the onset of symptoms and the time of first blood 
sampling was 13.9 hours (95%  CI, 11 .5 -16 .4 ).
Chemokines
MCP-1 and IL-8 were detectable in all patient samples at 
inclusion w ith a median value of 5 ,340 pg/m l (range 9 1 ­
445 ,60 0  pg/m l) and 9,541 pg/m l (range, 2 8 -4 2 7 ,5 0 0  pg/ml), 
respectively. MIP-1 a  was detectable in 33  out of 58  patients 
(57% ) w ith a median value of 164 pg/m l (range, 2 0 -9 ,7 8 4  pg / 
ml), and G R O -a  levels were detectable in 40 patients (69% ) 
w ith a median value of 892  pg/m l (range, 2 0 -1 0 1 ,1 5 0  pg/ml).
MIP-1 a, G RO  -a and MCP-1 levels were significantly higher in 
patients w ith septic shock than those in patients w ith sepsis 
(P  =  0.009, P  =  0 .005 and P  =  0 .006, respectively), whereas 
there was no significant difference in IL-8 levels between 
patients w ith sepsis and sep tic  shock (P  =  0.066).
Chemokine levels on admission strongly correlated w ith each 
other, as well as w ith levels of IL-6 and TNF-a w ith Spearman 
correlation coeffic ients ranging from 0.56 to 0.91 (data not 
shown). S ignificant differences were seen between survivors 
and nonsurvivors (M ann-W hitney U test, P  <  0 .0001) for all 
serum chemokine levels, as well as for the cytokines TNF-a 
and IL-6 (Figure 1). All nonsurvivors had higher levels of MCP- 
1, MIP-1 a, IL-8 and IL-6 com pared w ith survivors. Using 
receiver-operating characteristic curve analysis, cuto ff values 
of 65 ,407  pg/m l fo r MCP-1, 460  pg/m l for MIP-1 a, 85 ,427  
pg/m l for IL-8 and 361 ng/ml for IL-6 were determined, which 
all had 100%  sensitivity and a specific ity between 94%  and 
98%  in predicting nonsurvival.
W e found positive correlations between chemokine levels and 
PRISM scores (IL-8, rs =  0.72; MIP-1 a, rs =  0.67; G RO -a, rs =  
0 .70; and MCP-1, rs =  0.62; P  <  0 .0001) (Figure 2). Correla­
tion coeffic ients between MIP-1 a, G R O -a and MCP-1 and 
PRISM scores were higher than between TNFa levels and 
PRISM scores (rs =  0.56) and were slightly lower than 
between IL-6 and PRISM scores (rs =  0.73). High correlations 
were also found between serum chemokine levels and D is­
seminated Intravascular Coagulation scores, Sepsis-related 
Organ Failure Assessm ent scores and laboratory parameters 
for disease severity and activation of coagulation such as lac­
tate concentration, C-reactive protein and white blood cell 
counts, D-dimers and fibrinogen levels (Table 1). Furthermore, 
initial serum levels of MCP-1 and MIP-1 a, but not of G R O -a 
and IL-8, were negatively correlated w ith the interval between 
the appearance of petechiae and the time of blood sampling 
(both rs =  -0.28, P  =  0.037).
Eight out of nine nonsurvivors died within 24 hours after 
admission. Chemokine levels in available sera of children 24
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F igure  2
PRISM score PRISM score
•  non-survivors 
O survivors
Correlation betweenchemokine levels in serum samples of children with meningococcal sepsis or septic shock and Pediatric Risk of Mortality 
(PRISM) scores on admission. The horizontal lines in the charts for macrophage inflammatory protein 1 a  (MIP-1 a) and growth-related gene product 
alpha (GRO-a) indicate the detection limit for the assay. MCP-1, monocyte chemoattractant protein 1.
hours after pediatric intensive care unit admission (n =  49) 
showed a significant decrease (P  <  0.0001 fo r all chem ok­
ines) (Figure 3).
Discussion
A complex network of cytokines, com plement factors and 
coagulation and fibrinolysis factors are involved in the patho­
physiology of m eningococcal sepsis as a response to the very 
high loads of lipopolysaccharide and m eningococcal outer 
membrane proteins. Chemokines are involved in directing leu­
cocytes to the site of inflammation and are probably necessary 
for the translation of the innate immune response against path­
ogens into a specific  acquired response [22]. The present 
study demonstrates the presence of extremely high levels of
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F igure  3
Chemokinelevelsin serum samples of children with meningococcal sepsis or septic shock on admission and levels obtained 24 hours after admis­
sion to the pediatric intensive care unit (pg/ml). Black lines in boxes represent median values, boxes represent interquartile ranges, bars represent 
the 10th and 90th percentiles, and black dots are outlying values. GRO-a, growth-related gene product alpha; MCP-1, monocyte chemoattractant 
protein 1; MIP-1 a, macrophage inflammatory protein 1 a.
chemokines from the C C  family as well as the C X C  family in 
sera obtained from children in the initial phase of m eningococ­
cal sepsis or septic shock. This implies a generalized upregu-
lation of both chemokine families in the early stage of 
m eningococcal disease in children. Schinkel and colleagues 
showed earlier that chemokines of both families are readily
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produced within 2 hours after endotoxin challenge in healthy 
volunteers [23].
Median levels of IL-8, MCP-1 and MIP-1 a  were higher than 
those described in patients w ith m eningococcal meningitis 
[10,11]. Furthermore, peak M IP-1a levels were 20 times 
higher and IL-8 levels were 250 times higher than levels 
described in adult patients w ith sepsis [24].
MIP-1 a  and G R O -a  were moderately elevated or even unde­
tectable in moderately ill patients, but reached very high levels 
in the severely ill patients. MCP-1 and IL-8 serum levels were 
detectable in all patients and reached very high levels in 
severely ill patients, especially in nonsurvivors. These results 
are in accordance w ith those described by Moller and co l­
leagues, who showed that levels of MCP-1, IL-8 and MIP-1 a  
were significantly higher in patients w ith fulm inant meningoco- 
cal septicem ia as compared w ith patients w ith d istinct menin­
gitis or mild disease [25]. In addition, we show  strong 
significant differences between survivors and nonsurvivors in 
serum levels of MCP-1, MIP-1 a  and IL-8. Cuto ff values w ith 
100%  sensitivity and 9 4 -9 8 %  specific ity in predicting out­
come were calculated for these chemokines. This is in contrast 
to TNF -a, probably the most intensively studied cytokine in 
m eningococcal disease, for which a cuto ff value of 22.5 had a 
78%  sensitivity and 98%  specificity. IL-6, another cytokine 
known to be involved in m eningococcal sepsis, was also 
higher in all nonsurvivors than in survivors [26 ,27]. In our study, 
IL-6 had a cutoff value w ith a sim ilar sensitivity and specific ity 
as chemokines.
The inverse correlation between MCP-1 and MIP-1 a  and the 
interval between the appearance of petechiae suggests that 
these chemokines play a major role in severely ill patients in 
whom the course of disease is more rapid than in other 
patients. Chemokine levels also correlated w ith disease sever­
ity, as indicated by the high correlations between disease 
severity scores and laboratory parameters. Correlations 
between chemokine levels and PRISM scores were higher 
than correlations between TNF-a and PRISM scores, indicat­
ing that serum levels of these chemokines are a better p red ic­
tor for disease severity than TNF-a. Common polymorphisms 
in the MIP-1 a, MCP-1 and IL-8 genes have been recently d is­
covered and are associated w ith an increased production of 
these chemokines [28-30]. Further research is needed to 
determine the role of these genetic polymorphisms in the 
severity of m eningococcal disease in children.
The results of our study suggest that chemokine levels may be 
suitable candidates fo r implementation in prognostic scores 
based on laboratory parameters. Chemokines may play a key 
role in the pathophysiology of m eningococcal disease, and 
chemokines as well as their receptors are potentially new tar­
gets fo r therapeutic approaches. Chemokine receptor antago­
nists, antichemokine antibodies and broad-spectrum
chemokine inhibitors are currently under development [31,32]. 
Future research will have to show  their applicability in menin­
gococcal disease.
Conclusion
Serum levels of C X C  and C C  chemokines in children in the ini­
tial phase of m eningococcal sepsis can predict disease sever­
ity and outcome.
Key m essages
• Extremely high levels of C C  chemokines as well as C X C  
chemokines are found in sera from children in the initial 
phase of m eningococcal sepsis.
• Chemokine levels in children in the initial phase of 
m eningococcal sepsis accurately pred ict disease sever­
ity and outcome.
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